56 related articles for article (PubMed ID: 12710195)
1. Assays for cyclin-dependent kinase inhibitors.
Senderowicz AM; Lahusen T
Methods Mol Med; 2003; 85():39-48. PubMed ID: 12710195
[No Abstract] [Full Text] [Related]
2. Assays for cyclin-dependent kinase inhibitors.
Senderowicz AM
Methods Mol Biol; 2004; 285():69-78. PubMed ID: 15269400
[No Abstract] [Full Text] [Related]
3. Immunohistochemical assays of farnesyltransferase inhibition in patient samples.
Adjei AA
Methods Mol Med; 2003; 85():141-5. PubMed ID: 12710205
[No Abstract] [Full Text] [Related]
4. Screening with COMPARE analysis for telomerase inhibitors.
Naasani I; Yamori T; Tsuruo T
Methods Mol Biol; 2002; 191():197-207. PubMed ID: 11951607
[No Abstract] [Full Text] [Related]
5. Immunohistochemical determination of EGFR-tyrosine kinase inhibition in clinical samples.
Malik SN; Bedolla RG; Hidalgo M; Brattain MG; Kreisberg JI
Methods Mol Med; 2003; 85():135-40. PubMed ID: 12710204
[No Abstract] [Full Text] [Related]
6. Integrated technology platform protein kinases for drug development in oncology.
Sachsenmaier C; Schächtele C
Biotechniques; 2002 Oct; Suppl():101-6. PubMed ID: 12395934
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of 1,7-annulated indoles and their applications in the studies of cyclin dependent kinase inhibitors.
Zhu G; Conner SE; Zhou X; Chan HK; Shih C; Engler TA; Al-Awar RS; Brooks HB; Watkins SA; Spencer CD; Schultz RM; Dempsey JA; Considine EL; Patel BR; Ogg CA; Vasudevan V; Lytle ML
Bioorg Med Chem Lett; 2004 Jun; 14(12):3057-61. PubMed ID: 15149644
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinase inhibitors.
Fischer PM; Endicott J; Meijer L
Prog Cell Cycle Res; 2003; 5():235-48. PubMed ID: 14593718
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of 3,5-diaminoindazoles as cyclin-dependent kinase inhibitors.
Lee J; Choi H; Kim KH; Jeong S; Park JW; Baek CS; Lee SH
Bioorg Med Chem Lett; 2008 Apr; 18(7):2292-5. PubMed ID: 18353638
[TBL] [Abstract][Full Text] [Related]
10. 3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation.
Lin R; Lu Y; Wetter SK; Connolly PJ; Turchi IJ; Murray WV; Emanuel SL; Gruninger RH; Fuentes-Pesquera AR; Adams M; Pandey N; Moreno-Mazza S; Middleton SA; Jolliffe LK
Bioorg Med Chem Lett; 2005 May; 15(9):2221-4. PubMed ID: 15837297
[TBL] [Abstract][Full Text] [Related]
11. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors.
Fischer PM
Curr Opin Drug Discov Devel; 2001 Sep; 4(5):623-34. PubMed ID: 12825457
[TBL] [Abstract][Full Text] [Related]
12. Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode.
Finlay MR; Acton DG; Andrews DM; Barker AJ; Dennis M; Fisher E; Graham MA; Green CP; Heaton DW; Karoutchi G; Loddick SA; Morgentin R; Roberts A; Tucker JA; Weir HM
Bioorg Med Chem Lett; 2008 Aug; 18(15):4442-6. PubMed ID: 18617397
[TBL] [Abstract][Full Text] [Related]
13. Preferences for phosphorylation sites in the retinoblastoma protein of D-type cyclin-dependent kinases, Cdk4 and Cdk6, in vitro.
Takaki T; Fukasawa K; Suzuki-Takahashi I; Semba K; Kitagawa M; Taya Y; Hirai H
J Biochem; 2005 Mar; 137(3):381-6. PubMed ID: 15809340
[TBL] [Abstract][Full Text] [Related]
14. The evolving role of cyclin-dependent kinase inhibitors in cancer management.
Shapiro GI
Clin Adv Hematol Oncol; 2017 Mar; 15(3):174-177. PubMed ID: 28398270
[No Abstract] [Full Text] [Related]
15. Searching for selective cyclin-dependent kinase inhibitors to target the retinoblastoma/p16 cancer gene pathway.
Kubo A; Kaye FJ
J Natl Cancer Inst; 2001 Mar; 93(6):415-7. PubMed ID: 11259459
[No Abstract] [Full Text] [Related]
16. New fascaplysin-based CDK4-specific inhibitors: design, synthesis and biological activity.
Aubry C; Jenkins PR; Mahale S; Chaudhuri B; Maréchal JD; Sutcliffe MJ
Chem Commun (Camb); 2004 Aug; (15):1696-7. PubMed ID: 15278142
[TBL] [Abstract][Full Text] [Related]
17. 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.
Lin R; Connolly PJ; Huang S; Wetter SK; Lu Y; Murray WV; Emanuel SL; Gruninger RH; Fuentes-Pesquera AR; Rugg CA; Middleton SA; Jolliffe LK
J Med Chem; 2005 Jun; 48(13):4208-11. PubMed ID: 15974571
[TBL] [Abstract][Full Text] [Related]
18. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells.
Pedranzini L; Dechow T; Berishaj M; Comenzo R; Zhou P; Azare J; Bornmann W; Bromberg J
Cancer Res; 2006 Oct; 66(19):9714-21. PubMed ID: 17018630
[TBL] [Abstract][Full Text] [Related]
19. Farnesyl transferase inhibitors.
Li T; Sparano JA
Cancer Invest; 2008 Aug; 26(7):653-61. PubMed ID: 18665473
[No Abstract] [Full Text] [Related]
20. Letter by Krötz et al regarding article, "Improvement of peripheral endothelial dysfunction by protein tyrosine phosphatase inhibitors in heart failure".
Krötz F; Sohn HY; Mannell H
Circulation; 2007 Jun; 115(25):e648; author reply e649. PubMed ID: 17592086
[No Abstract] [Full Text] [Related]
[Next] [New Search]